LFB USA, Inc.

Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas, May 13, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Board of Directors has appointed Jose A. Moreno Toscano as non-executive Chairman of the Board following the sudden passing of the Company's co-founder and previous Chairman Rodney Varner. Prior to his appointment as Chairman, Mr. Moreno Toscano has served on Genprex's Board of Directors since March 2020. Since April 2018, Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc, the US subsidiary of LFB Group, a global integrated biopharmaceutical company, and he has more than 20 years of experience in the pharmaceutical and biotechnology industries, building, developing and transforming organizations. Mr. Moreno Toscano has a successful track record of identifying and capitalizing on opportunities to drive exponential revenue growth and market expansion, revitalizing underperforming operations and establishing foundations for successful start-up operations. His experience includes strategic planning, corporate restructuring, business development, M&A, investor relations and general management. Mr. Moreno Toscano's appointment follows the recent appointment of Ryan Confer to serve as Genprex's President and Chief Executive Officer. Mr. Confer was also appointed to Genprex's Board of Directors. Mr. Moreno Toscano commented: "On behalf of Genprex's Board of Directors, we wish to express our support for Ryan as Genprex's new President and Chief Executive Officer. We have worked closely with Ryan over the last several years, and we have seen his robust leadership skills and exceptional operational organization. He has strengthened the company's operational and financial foundation, bolstered the company's talent and culture, added value in every company department and has continuously advanced the company's strategies year after year. I look forward to working alongside Ryan and our other fellow directors in my role as Chairman in what I believe will be a transformational time for Genprex." About Genprex, Inc. Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. The Company's lead product candidate, Reqorsa® Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC. Each of Genprex's three lung cancer clinical programs has received a Fast Track Designation from the FDA for the treatment of that patient population, and Genprex's SCLC program has received an FDA Orphan Drug Designation. Genprex's diabetes gene therapy approach is comprised of a novel infusion process that uses an AAV vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but may be distinct enough from beta cells to evade the body's immune system. In a similar approach, GPX-002 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells. Interested investors and shareholders are encouraged to sign up for press releases and industry updates by visiting the Company Website, registering for Email Alerts and by following Genprex on Twitter, Facebook and LinkedIn. Cautionary Language Concerning Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of management, are not guarantees of performance and are subject to significant risks and uncertainty. These forward-looking statements should, therefore, be considered in light of various important factors, including those set forth in Genprex's reports that it files from time to time with the Securities and Exchange Commission and which you should review, including those statements under "Item 1A – Risk Factors" in Genprex's Annual Report on Form 10-K for the year ended December 31, 2023. Because forward-looking statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: the appointment and transition of management personnel and other succession plan-related activities; Genprex's ability to advance the clinical development, manufacturing and commercialization of its product candidates in accordance with projected timelines and specifications; the timing and success of Genprex's clinical trials and regulatory approvals; the effect of Genprex's product candidates, alone and in combination with other therapies, on cancer and diabetes; Genprex's future growth and financial status, including Genprex's ability to maintain compliance with the continued listing requirements of The Nasdaq Capital Market and to continue as a going concern and to obtain capital to meet its long-term liquidity needs on acceptable terms, or at all; Genprex's commercial and strategic partnerships, including those with its third party vendors, suppliers and manufacturers and their ability to successfully perform and scale up the manufacture of its product candidates; and Genprex's intellectual property and licenses. These forward-looking statements should not be relied upon as predictions of future events and Genprex cannot assure you that the events or circumstances discussed or reflected in these statements will be achieved or will occur. If such forward-looking statements prove to be inaccurate, the inaccuracy may be material. You should not regard these statements as a representation or warranty by Genprex or any other person that Genprex will achieve its objectives and plans in any specified timeframe, or at all. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Genprex disclaims any obligation to publicly update or release any revisions to these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events, except as required by law. Genprex, Inc. (877) 774-GNPX (4679) GNPX Investor Relations [email protected] GNPX Media Contact Kalyn Dabbs [email protected] SOURCE Genprex, Inc.

▲8月03-04日 CMC-China大会 · 限时免费扫码报名中注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需得到授权。多发性硬化症(multiple sclerosis,MS)是中枢神经系统（CNS）的慢性脱髓鞘疾病，是中枢神经系统最常见的慢性炎症性疾病，包括复发-缓解型多发性硬化（RRMS）患者和持续复发的继发性进行性多发性硬化（SPMS）患者。多发性硬化发生在中枢神经系统，由自身免疫系统攻击髓鞘引起。髓鞘是包裹和保护大脑和脊髓中神经纤维的脂质物。疾病导致的炎症和组织损伤会破坏大脑、视神经和脊髓的正常功能。临床症状表现为极度疲劳、麻木、虚弱、视力困难等。病因尚不明确，可能与遗传、环境、病毒感染等多种因素相关。主要发病年龄在20至40岁，是仅次于创伤的中青年人致残原因，目前尚无治愈性疗法。根据《中国多发性硬化患者综合社会调查报告》统计，中国患病率较低，高纬度高发。高加索人种有着更高的患病率，约50-300/10万人，远高于亚洲人，海外市场空间巨大。药融圈旗下，药融云数据www.pharnexcloud.com显示：2022年12月28日，美国FDA批准TG Therapeutics的CD20单抗Briumvi®（Ublituximab-XIIY）上市，用于治疗复发型多发性硬化症(RMS)，包括成人的临床孤立综合征、复发缓解型疾病和活动性继发性进展性疾病。2023年1月26日，该公司宣布在美国商业推出Briumvi®（Ublituximab-XIIY）。截至2023年3月31日，TG治疗从Briumvi的药品销售中获得了780万美元的收入。2023年6月1日，TG治疗公司宣布，欧盟委员会（EC）已批准Briumvi®（Ublituximab-XIIY）用于治疗患有复发性多发性硬化症（RMS）的成年患者，这些患者的活动性疾病由临床或影像学特征确定。有了这一批准，集中上市许可现在在所有欧盟（EU）成员国、冰岛、挪威和列支敦士登都有效。抗CD20抗体已经改变了复发性多发性硬化症患者的治疗前景在美国，每年约8万患者都会开始首次或转换到新的多发性硬化症治疗；50%以上的患者会选择抗CD20抗体作为一种新的多发性硬化症治疗；大于10万多发性硬化症患者目前正在使用抗CD20抗体。TG治疗公司称，Briumvi有潜力成为美国市场No.1 CD20单抗处方药。该公司董事长兼首席执行官Michael S. Weiss表示：“我们非常高兴欧盟委员会批准Briumvi用于治疗患有多发性硬化症的成年患者。这使我们离为欧洲多发性硬化症患者提供替代治疗方案的目标更近了一步，该治疗方案可以在开始剂量后每6个月输注一小时，我们的目标是在今年晚些时候投入商业使用。”TG Therapeutics公司总裁兼CEO-Michael S.Weiss 公司简介 TG Therapeutics（TGTX）是一家全面整合、处于商业化阶段的生物制药公司，专注于B细胞疾病新疗法的收购、开发和商业化。于1993年在美国特拉华州注册成立，2005年10月上市纳斯达克，截至2023年5月1日，公司拥有237名全职员工。目前公司市值约37亿美元。TG治疗公司已获得美国食品和药物管理局(FDA)批准BRIUMVI(ublituximab-xiiy)用于治疗复发型多发性硬化症(RMS)成年患者，包括成人中的临床孤立综合征、复发-缓解性疾病和活动性继发性进行性疾病，BRIUMVI也是该公司目前唯一上市的产品。该公司正在开发用于B细胞疾病的TG-1701（BTK抑制剂）和TG-1801（抗CD47/CD19双特异性抗体），目前正在进行1期临床试验。 三款候选药物 TG治疗公司候选药物的临床试验状态-截至2023年4月01Briumvi（Ublituximab-XIIY）Briumvi旨在实现高效的B细胞低剂量耗竭Briumvi是第一个也是唯一一个获批用于RMS患者的抗CD20单克隆抗体。Briumvi是一款糖工程化单克隆抗体，靶向B细胞表达的CD20抗原上的独特抗原表位。当Briumvi与B细胞结合时，可以引发抗体依赖性细胞毒性（ADCC）和补体依赖性细胞毒性（CDC）等一系列免疫反应以摧毁致病B细胞。这些细胞被认为是导致髓鞘和神经细胞轴突损伤的关键因素。Briumvi的一个独特之处在于通过糖工程化去除了抗体中某些糖分子，显从而著增强Briumvi的效力，尤其是ADCC活性。Briumvi的批准主要基于UltimateI和UltimateII3期试验。每项试验均为独立、全面、随机、多中心、双盲、双模拟、活性对照研究，比较了ublituximab（每6个月静脉滴注1小时，剂量为450mg，随后在4小时内滴注1次150mg，在1小时内滴注15次450mg）与teriflunomide（每日一次口服14mg片剂）对RMS受试者的疗效和安全性/耐受性。这些试验是在FDA的特殊方案评估（SPA）下进行的。最终的I和II试验由医学博士劳伦斯·斯坦曼（Lawrence Steinman）领导，全部招募工作于2018年10月完成，两项研究共招募了约1，100名受试者。2020年12月，该公司宣布了最终I和II试验的积极结果。两项研究均在96周内达到了显著降低ARR的主要终点（每项研究中P<0.005），Briumvi在每项研究中的ARR均<0.10。与teriflunomide相比，在UltimateI和II中分别观察到ARR相对降低约60%和50%。也达到了关键的次要MRI终点。2022年8月22日，《新英格兰医学杂志》（New England Journal of Medicine）发表了最终I和II试验的完整结果。2022年12月28日，TG治疗公司宣布FDA批准Briumvi用于治疗成人RMS，包括临床孤立综合征、复发-缓解型疾病和活动性继发性进展性疾病，主要基于最终I和II3期试验的结果。02TG-1701 (BTK 抑制剂）TG-1701是一种新型的、口服的、共价结合的Bruton酪氨酸激酶（BTK）抑制剂，在体外激酶筛选中对BTK表现出很强的选择性。在B细胞白血病或淋巴瘤患者中，B细胞受体（BCR）信号传导对正常B细胞发育至关重要，并支持恶性B细胞的存活和生长。靶向BTK是BCR信号通路的基本元件，调节B淋巴细胞的存活、活化、增殖和分化，在B细胞恶性肿瘤中显示出显著的疗效和可接受的安全性。该公司目前正在评估TG-1701在B细胞恶性肿瘤患者中的1期、多中心、剂量递增临床试验。关键的次要目标包括药代动力学（PK）、药效学和初步抗癌活性的评估。该试验的数据在2021年美国血液学会（ASH）年会上公布。本品最早由恒瑞医药研发，代号为SHR1459。03TG-1801(抗CD47/抗CD19双特异性单克隆抗体)G-1801是第一类双特异性CD47和CD19抗体。这是第一个同时靶向CD19和CD47的疗法，CD19是一种在B细胞恶性肿瘤中广泛表达的B细胞特异性市场，CD47是健康细胞和肿瘤细胞用来逃避巨噬细胞介导的吞噬作用的“不要吃我”信号。CD47在正常细胞上广泛表达，包括红细胞和血小板。CD19是一种特异性B细胞标记物，在前B细胞个体发育早期表达，直到终末分化为早期浆细胞。大多数B细胞系恶性肿瘤（90%以上）表达CD19，包括非霍奇金淋巴瘤（NHL）、慢性淋巴细胞白血病（CLL）和急性淋巴细胞白血病（ALL）。已经发现在抗CD20mAb治疗后失去CD20表达的肿瘤B细胞维持CD19的表达，使得CD19成为治疗B细胞恶性肿瘤的有吸引力的靶标。2019年第一季度，TG治疗公司开始了TG-1801的1期首次人体剂量递增研究。这项研究正在评估在B细胞淋巴瘤患者中逐步增加TG-1801的剂量。该研究的主要目的是确定推荐的2期剂量，并描述TG-1801的安全性。关键的次要目标是评估TG-1801的药代动力学及其初步抗癌活性。2022年12月，在第64届美国血液学会（ASH）年会暨博览会上公布了这项首次人体1期研究的初步结果。TG-1801单药治疗和与Ublituximab联合治疗耐受性良好，未发现MTD，并在多种复发性或难治性B细胞淋巴瘤中表现出初步疗效。2021年上半年，TG治疗在美国开始了TG-1801的第二个1期研究，以继续优化单药治疗和与Ublituximab联合治疗的剂量，该研究的招募工作仍在进行中。TG治疗公司许可协议合作情况TG治疗与多家公司结成了战略联盟以生产和销售产品，以下是该公司目前主要许可协议合作情况：01BRIUMVI(ublituximab-xiiy)—LFB BiotechnologiesS.A.S，GTC Biotherapeutics，LFB/GTCLLC2012年1月，TG治疗与LFB集团的全资子公司LFB Biotechnologies、GTC Biotherapeutics和LFB/GTCLLC就Ublituximab的开发签订了独家许可协议（LFB许可协议）。根据LFB许可协议的条款，TG治疗获得了开发和商业化Ublituximab的全球独家权利（法国/比利时除外）。截至2022年12月31日，根据LFB许可协议的条款，已支付约2500万美元的里程碑相关费用，其中1200万美元与FDA批准Briumvi相关的里程碑相关。在实现某些监管里程碑后，LFB集团有资格获得约600万美元的未来付款。ILDONG PharmaceuticalCo.Ltd.(ILDONG)2012年11月，TG治疗与ILDONG就Ublituximab在韩国和东南亚的开发和商业化签订了独家（区域内）分许可协议。根据分许可协议的条款，ILDONG已被授予特许权使用费，包括授予分许可的权利，以在韩国、台湾、新加坡、印度尼西亚、马来西亚、泰国、菲律宾、越南和缅甸开发和商业化Ublituximab。到目前为止，ILDONG已经从ILDONG收到了200万美元的预付款，并有资格获得总额高达500万美元的基于销售的里程碑付款，以及Ublituximab净销售额的特许权使用费。02TG-1701（BTK抑制剂）2018年1月，TG治疗与江苏恒瑞签订了一份全球独家许可协议，以获得全球知识产权（不包括亚洲，但包括日本），并研究、开发、制造和商业化含有或包含任何恒瑞Bruton酪氨酸激酶抑制剂（含有TG1701（SHR1459或EBI1459）或TG1702（SHR1266或EBI1266）化合物）的产品。恒瑞有资格在实现某些里程碑后获得总计约3.5亿美元的里程碑付款。2020年7月，TG治疗根据许可协议向恒瑞支付了200万美元，作为里程碑的一部分。03TG-1801（抗CD47/抗CD19双特异性抗体）2018年6月，TG治疗与Novimmune签订了一项合资和许可选择协议，以合作开发和商业化Novimmune的新型一流抗CD47/抗CD19双特异性抗体TG1801（之前为Ni1701）。两家公司将在全球范围内联合开发该产品，重点关注血液B细胞恶性肿瘤领域的适应症。TG治疗是产品开发、制造和商业化的主要责任方。里程碑付款将根据早期临床开发支付，TG治疗将负责该产品的临床开发费用，直至2期临床试验结束，之后公司和Novimmune将共同负责所有开发和商业化费用。TG治疗及Novimmune将各自保留独家选择权，可在开发期间的特定时间行使对TG1801的许可权，在这种情况下，Novimmune有资格获得总额约为1.85亿美元的额外里程碑付款。04UKONIQ（umbralisib）2014年9月，TG治疗行使了向Umbralisib授予全球许可权的选择权，从而与Rhizen Pharmaceuticals，SA（Rhizen）就Umbralisib的开发和商业化达成了独家许可协议（Umbralisib许可）。Rhizen有资格获得批准和基于销售的里程碑付款，总额约为1.75亿美元。05Cosibelimab2015年3月，TG治疗与Checkpoint Therapeutics，Inc.达成全球合作（合作协议）。（Checkpoint）用于开发和商业化Checkpoint在血液恶性肿瘤领域的抗PD-L1和抗GITR抗体研究项目，并可选择获得自身免疫性疾病的权利。根据协议条款，TG治疗将支付总额约为1.1亿美元的开发和销售里程碑付款，并将为净销售额支付低两位数的分级特许权使用费。财务状况自成立以来，TG治疗公司遭受了重大的经营亏损，几乎所有的经营亏损都是由与研发项目有关的成本以及与经营（包括商业化活动）有关的销售、一般和管理成本造成的。截至2023年3月31日，TG治疗公司累计赤字为16亿美元，主要现金来源是私募和公开发行股权证券的收益，以及与Hercules Capital，Inc.签署的贷款和担保协议的收益。截至2023年3月31日，TG治疗公司拥有1.397亿美元的现金和现金等价物以及投资证券。2022财年TG治疗公司产品营收278.5万美元，相较于上一年营收668.9万美元有所减少，原因是该公司此前唯一一款商业化产品UKONIQ于2022年5月自愿退出市场，导致产品净收入减少。2022年TG治疗公司总研发成本1.25亿美元，净亏损1.98亿美元。2023年5月8日，TG治疗公司公布2023年一季度报告。2023Q1 TG治疗公司实现营收780.3万美元，而2022年Q1营收约为200万美元，超出市场预期130.86%；每股收益为-0.28美元，前值为-0.51美元，预期值为-0.37美元，超出市场预期24.32%。研发费用方面，2023Q1总研发费用为1587万美元，而在2022年Q1该值为4804.2万美元。2023年1月，TG治疗公司在FDA批准后开始在美国境内进行BRIUMVI的商业销售。截至2 023年3月31日，该公司从Briumvi的药品销售中获得了780万美元的收入。2023年Q1TG治疗公司经营活动中使用的现金为5990万美元，而上一年同期为6870万美元，经营活动中使用的净现金减少主要是由于与生产和临床试验费用相关的支出减少。此外，2023年Q1该公司融资活动产生的净现金为2520万美元，而2022年Q1融资活动产生的净现金为90万美元。融资活动产生净现金的增加主要是由于在2023年3月31日与Hercules签订的第一修正案中提取了2500万美元的预付款。发展战略作为一家全面整合的商业化生物制药公司，TG治疗专注于B细胞疾病新疗法的收购、开发和商业化，该公司发展战略：在美国成功将治疗复发性多发性硬化症的Briumvi商业化；在Briumvi批准的基础上，评估Briumvi在其他MS适应症和/或其他自身免疫性疾病中的其他用途；继续扩大对B细胞介导疾病的重要机制的产品线；评估潜在的战略合作，以最大限度地提高B细胞定向平台的价值；发展业务的同时，保持“患者至上”的文化。参考：NMPA/CDE；药融云数据，www.pharnexcloud.com；FDA/EMA/PMDA；相关公司公开披露（除标注外，正文图片均来自企业官方）；https://www.tgtherapeutics.comhttps://ir.tgtherapeutics.com/eventshttps://mp.weixin.qq.com/s/fiTXcXjTiJeOQv_mzKBjuQhttps://Briumvi.com/about-Briumvi/see-the-results点分享点点赞点在看

LES ULIS, France--(BUSINESS WIRE)-- LFB today announced that the European Medicines Agency (EMA) has granted on July 15th a Marketing Authorisation for CEVENFACTA® (eptacog beta), as the first new bypassing agent in over 20 years. CEVENFACTA® is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups: in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ≥5 Bethesda Units (BU)); in patients with congenital haemophilia with low titre inhibitors (BU <5), but expected to have a high anamnestic response to factor VIII or factor IX administration or expected to be refractory to increased dosing of FVIII or FIX. Denis Delval, LFB’s Chairman and Chief Executive Officer, stated: “We are very pleased with the approval of CEVENFACTA® by the EMA, which provides a new treatment option for haemophilia patients with inhibitors in the European Union. This approval is a validation of our innovative LFB technology and the acknowledgement of LFB’s deep commitment to patients.” Dr. Patrick Delavault, MD, LFB’s Executive Vice President Scientific, Medical and Regulatory Affairs, stated: “We need to keep in mind constantly what a bleeding event, even a single bleeding event, means to a haemophilia patient with inhibitors and to his family. This novel treatment alternative is a significative opportunity to improve patients’ lives”. LFB has been granted a Marketing Authorisation for SEVENFACT® (eptacog beta) in Mexico on June 2nd for the treatment of bleeding episodes in adults and adolescents with haemophilia A or B with inhibitors. About PERSEPT studies: The approval of CEVENFACTA® was based on data from the phase III clinical trials, PERSEPT 1 and PERSEPT 3. The PERSEPT 1 Phase III, multicentre, randomised, open-label crossover study of two initial dose regimens (75µg/kg and 225µg/kg), evaluated 468 bleeding episodes across the full type of severity of bleeding episodes (mild, moderate, and severe), in 27 adolescent and adult haemophilia A and B patients with inhibitors (12-54 years of age). Both dosing regimens met the primary endpoint with 81% and 90% of bleeds controlled at 12 hours with the 75µg/kg dose and the 225µg/kg dose respectively. By 24 hours, haemostatic efficacy (secondary endpoint) was retained in 96.7% of bleeding episodes treated with the 75 µg/kg dose regimen and 99.5% of redundancy bleeding episodes treated with the 225 µg/kg dose, without requiring any alternative therapy. The median time to attain haemostatic efficacy was 5.98 hours for the 75 µg/kg dosing regimen and 3 hours for the 225 µg/kg dosing regimen. A median of 2 injections was needed to treat a bleeding episode with the 75 µg/kg and a median of only 1 injection of the 225 µg/kg dosing regimen was needed. The PERSEPT 3 Phase III, multicentre, open-label, single-arm study evaluated the safety and efficacy of CEVENFACTA® in haemophilia A or B patients with inhibitors who were scheduled for an elective surgical or other invasive procedure. 12 patients were enrolled in the study, 6 with minor procedures and 6 with major procedures. For major surgical/invasive procedures, treatment was administered at an initial bolus dose of 200 µg/kg immediately before the start of the invasive procedure. For a minor elective surgical procedure, an initial bolus dose of 75 µg/kg was administered immediately before the start of the procedure. Overall, 81.8% of procedures were reported as successfully treated at 48 hours after the last administration of the product. No thromboembolic events were reported in these two clinical trials. No Serious Adverse Events (SAEs) were considered as related to the treatment. Patients should be monitored for any signs of thrombosis, hypersensitivity and neutralising antibodies. The most frequently reported adverse reactions in studies were infusion site discomfort, infusion site haematoma, post-procedural haematoma, infusion related reaction, increased body temperature, dizziness and headache. About LFB LFB is a bio-pharmaceutical group that develops, manufactures and markets plasma derived products and recombinant proteins for the treatment of patients with serious and often rare diseases. LFB was founded in 1994 in France and is among the leading European bio-pharmaceutical companies providing mainly hospital-based healthcare professionals with blood-derived therapeutics with the vision to provide treatment options to patients in three major areas: immunology, haemostasis, and intensive care. LFB currently markets 15 biomedicinal products in more than 30 countries. Please visit www.groupe-lfb.com for further information on LFB.